AGP Picks
View all

OptraSCAN to debut FDA-cleared OS-Ultra scanner at Pathology Visions 2026

Oct. 13, 2026
OptraSCAN to debut FDA-cleared OS-Ultra scanner at Pathology Visions 2026
By AI, Created 12:00 UTC, Oct 13, 2026, AGP -

OptraSCAN will publicly unveil its FDA-cleared OS-Ultra whole slide scanner at Pathology Visions 2026 in San Diego on Oct. 16-18. The clearance gives laboratories a new digital pathology system option with direct purchase or pay-per-use access starting in December.

Why it matters: - The FDA clearance gives OptraSCAN its first regulatory-reviewed digital pathology system and could lower adoption barriers for laboratories that have delayed digital pathology because of cost or regulatory uncertainty. - The OS-Ultra sits at the center of the OptraSCAN System, so the clearance expands the company’s commercial position beyond standalone scanners. - The pay-per-use option may make the system more accessible to labs that want to scan digitally without a large upfront capital investment.

What happened: - OptraSCAN said it will unveil the FDA-cleared OS-Ultra whole slide scanner at the Digital Pathology Association’s Pathology Visions 2026 conference in San Diego on Oct. 16-18. - The scanner will make its first public appearance at booth 417. - The OS-Ultra is the scanner at the core of the OptraSCAN System, which received FDA 510(k) clearance in July for HER2 image analysis of formalin-fixed, paraffin-embedded breast tissue stained with the Dako HercepTest. - The FDA-cleared OS-Ultra will be available starting in December.

The details: - The OS-Ultra is OptraSCAN’s highest-throughput scanner. - It captures a 15 mm by 15 mm tissue area at 40x in under 60 seconds. - The scanner holds between 80 and 480 slides, depending on configuration. - Continuous loading lets histotechnologists add racks without stopping a run. - Images are delivered in open, standards-based formats, including DICOM. - Those formats are designed to move into image management systems, viewers and AI tools from OptraSCAN or other vendors. - Existing OS-Ultra installations remain fully supported. - OptraSCAN said its systems are installed at more than 165 sites in over 30 countries. - The company is headquartered in San Jose, California.

Between the lines: - The clearance positions OptraSCAN as more than a hardware vendor by tying the scanner to a cleared workflow for clinical use. - The DICOM and open-format support suggests OptraSCAN is aiming for interoperability in labs that already use mixed-vendor software and AI tools. - The combination of direct purchase and pay-per-use points to a sales strategy built around both capital buyers and labs that prefer operational spending.

What's next: - Laboratories can buy the FDA-cleared OS-Ultra directly or use the pay-per-use model starting in December. - Attendees at Pathology Visions 2026 can see the system in person at booth 417. - OptraSCAN is directing interested buyers to request a demonstration or contact info@optrascan.com. - The company also directs readers to learn more at www.optrascan.com.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

California Business Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

California Business Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.